Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna .

The Trump administration confirmed it is reevaluating a $590 million human bird flu vaccine contract awarded to Moderna in ...

A big legal victory across the Atlantic Ocean was the news propelling Moderna (NASDAQ: MRNA) stock to a significant price ...

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market.

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...

Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in adults 60 ...

The court said Pfizer and BioNTech would have to provide information on earnings derived from the use of the patent and that ...

Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top ...

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the Medicines and Healthcare products ...

Moderna, Inc. ( NASDAQ: MRNA) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET All right, well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.